Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 16/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19483388 | 1.00 | CPB2 (0.40) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL19483460 | 0.78 | SCN9A (0.42) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL19143543 | 0.76 | CPB2 (0.53) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL22361422 | 0.74 | SCN9A (0.44) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL16508860 | 0.74 | CPB2 (0.51) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL15925123 | 0.73 | CPB2 (0.41) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL12793202 | 0.73 | CYP2C9 (0.45) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL19483360 | 0.72 | CYP1A2 (0.50) | TSHRCYP2C19 | |
| SCHEMBL19483382 | 0.72 | CYP1A2 (0.50) | TSHRCYP2C19 | |
| SCHEMBL14664160 | 0.71 | CYP2C9 (0.46) | CPB2CPB1CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | CPB2 236/4885CPB1 157/4885CYP2C9 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.